Year archive

Cellectis — 2024 filings

All 104 regulatory filings released by Cellectis (ALCLS) in 2024, sourced directly from the official regulator.

104 Filings

2024 Period

2024 filings (104)

Filing	Released	Lang
FORM 6-K Foreign Filer Report	2024-12-10	English
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) Capital/Financing Update	2024-12-10	English
Cellectis annonce le tirage de la troisième tranche de 5 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (BEI) Capital/Financing Update	2024-12-10	French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-12-04	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-12-04	English
FORM 6-K Foreign Filer Report	2024-11-05	English
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting Regulatory Filings	2024-11-05	English
Cellectis présente de multiples stratégies pour améliorer l'efficacité des cellules CAR T dans les tumeurs solides à la réunion annuelle de la SITC Regulatory Filings	2024-11-05	French
6-K Foreign Filer Report	2024-11-04	English
FORM 6-K Foreign Filer Report	2024-10-30	English
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024 Earnings Release Q3 2024	2024-10-30	French
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 Report Publication Announcement	2024-10-30	English
FORM 6-K Foreign Filer Report	2024-10-22	English
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress Regulatory Filings	2024-10-22	English
Cellectis présentera des données sur des TALE Base Editors ainsi que sur son programme de thérapie génique non-virale lors du 31ème congrès annuel de l’ESGCT Regulatory Filings	2024-10-22	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-10-02	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-10-02	French
6-K/A Foreign Filer Report	2024-09-11	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-09-04	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-09-04	English
FORM 6-K Foreign Filer Report	2024-09-03	English
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety Regulatory Filings	2024-09-03	English
Cellectis présente des preuves précliniques de l’efficacité des cellules CAR T MUC1 contre le cancer du sein triple négatif tout en préservant la sécurité Regulatory Filings	2024-09-03	French
FORM 6-K Foreign Filer Report	2024-08-26	English
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors Regulatory Filings	2024-08-26	English
Cellectis publie un article dans Molecular Therapy sur la conception de cellules CAR T pour le traitement de tumeurs solides récalcitrantes Regulatory Filings	2024-08-26	French
FORM 6-K Foreign Filer Report	2024-08-07	English
Cellectis nomme le docteur Adrian Kilcoyne directeur médical Board/Management Information	2024-08-07	French
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer Board/Management Information	2024-08-07	English
6-K Foreign Filer Report	2024-08-06	English
Cellectis publie ses résultats financiers du deuxième trimestre 2024 Earnings Release Q2 2024	2024-08-06	French
Cellectis Provides Financial Results for the Second Quarter 2024 Interim / Quarterly Report H1 2024	2024-08-06	English
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-08-05	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-08-05	French
FORM 6-K Foreign Filer Report	2024-08-01	English
La FDA accorde le statut de médicament orphelin à CLLS52 (alemtuzumab) de Cellectis pour le traitement de la LLA Regulatory Filings	2024-08-01	French
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment Regulatory Filings	2024-08-01	English
FORM 6-K Foreign Filer Report	2024-07-25	English
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment Regulatory Filings	2024-07-25	English
La FDA accorde le statut de médicament orphelin et médicament pour une maladie pédiatrique rare (Rare Pediatric Disease Designation-RPDD) au produit candidat de Cellectis UCART22 pour le traitement de Regulatory Filings	2024-07-25	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-07-05	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-07-05	French
6-K Foreign Filer Report	2024-06-28	English
FORM 6-K Foreign Filer Report	2024-06-28	English
Résultats de l’Assemblée Générale Mixte de Cellectis du 28 juin 2024 AGM Information	2024-06-28	French
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 AGM Information	2024-06-28	English
FORM 6-K Foreign Filer Report	2024-06-20	English
Cellectis publie un article scientifique dévoilant trois facteurs clés pour une édition efficace avec des TALE base editors Regulatory Filings	2024-06-20	French
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing Regulatory Filings	2024-06-20	English
FORM 6-K Foreign Filer Report	2024-06-12	English
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications Regulatory Filings	2024-06-12	French
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications Regulatory Filings	2024-06-12	English
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-06-05	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-06-05	French
FORM 6-K Foreign Filer Report	2024-06-04	English
Cellectis obtient la désignation de médicament orphelin pour son produit CAR T allogénique UCART22 pour les patients atteints de leucémie lymphoblastique aiguë Regulatory Filings	2024-06-04	French
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia Regulatory Filings	2024-06-04	English
FORM 6-K Foreign Filer Report	2024-05-29	English
L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024 Report Publication Announcement	2024-05-29	French
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024 AGM Information	2024-05-29	English
FORM 6-K Foreign Filer Report	2024-05-28	English
Cellectis Reports Financial Results for First Quarter 2024 Earnings Release Q1 2024	2024-05-28	English
Cellectis publie ses résultats financiers du premier trimestre 2024 Earnings Release Q1 2024	2024-05-28	French
6-K Foreign Filer Report	2024-05-28	English
FORM 6-K Foreign Filer Report	2024-05-28	English
Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024 Earnings Release Q1 2024	2024-05-27	French
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 Report Publication Announcement	2024-05-27	English
FORM 6-K Foreign Filer Report	2024-05-24	English
SC 13D/A Major Shareholding Notification	2024-05-21	English
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-05-16	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-05-16	French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-05-06	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-05-06	English
FORM 6-K Foreign Filer Report	2024-05-06	English
Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca Share Issue/Capital Change	2024-05-06	French
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca Major Shareholding Notification	2024-05-06	English
6-K Foreign Filer Report	2024-05-03	English
Cellectis nomme Arthur Stril directeur financier par intérim Board/Management Information	2024-05-02	French
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer Board/Management Information	2024-05-02	English
20-F Annual Report FY 2023	2024-04-29	English
Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 Earnings Release Q4 2023	2024-04-29	French
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 Earnings Release Q4 2023	2024-04-29	English
FORM 6-K Foreign Filer Report	2024-04-22	English
Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs) Regulatory Filings	2024-04-22	French
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs Regulatory Filings	2024-04-22	English
FORM 6-K Foreign Filer Report	2024-04-10	English
Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiées Regulatory Filings	2024-04-10	French
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs Regulatory Filings	2024-04-10	English
FORM 6-K Foreign Filer Report	2024-04-08	English
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting Regulatory Filings	2024-04-08	English
Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCT Investor Presentation	2024-04-08	French
CORRECTION : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-04-05	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-04-04	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-04-04	French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-03-04	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-03-04	English
SC 13G/A Major Shareholding Notification	2024-02-14	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Share Issue/Capital Change	2024-02-02	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-02-02	English
FORM 6-K Foreign Filer Report	2024-01-16	English
Cellectis annonce le tirage de la deuxième tranche de 15 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (la « BEI ») Capital/Financing Update	2024-01-16	French
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) Capital/Financing Update	2024-01-16	English
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2024-01-08	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-01-08	French

Filings by year

2026 21 filings
2025 96 filings
2024 104 filings
2023 173 filings
2022 144 filings
2021 103 filings
2020 106 filings
2019 68 filings
2018 88 filings
2017 150 filings
2016 76 filings
2015 98 filings
2014 71 filings
2013 6 filings
2009 2 filings
2008 3 filings